Using surfactant in preterm newborns with NRDS or NARDS
Official title: Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)
Run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · NCT04777760 · Data updated 2026-11-12
This research will try to see if giving one dose versus two or more doses of surfactant helps preterm infants with NRDS or NARDS.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Minute to 24 Hours |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | January 1, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT04777760 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Preterm infants under 37 weeks gestation admitted to the participating NICU within 24 hours of birth who are diagnosed with NRDS or NARDS and receive at least one dose of surfactant, without major congenital or chromosomal anomalies or upper airway defects, are eligible.
✕Probably not a fit
Term infants, those with major congenital or chromosomal abnormalities or upper airway defects, and infants not treated in the participating NICU are unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study of preterm infants (<37 weeks) admitted to a NICU within 24 hours who are diagnosed with neonatal respiratory distress syndrome (NRDS) or neonatal ARDS (NARDS) and receive at least one dose of pulmonary surfactant. Participants will be grouped by whether they received a single dose or multiple doses of surfactant and their clinical outcomes (including bronchopulmonary dysplasia and death) will be recorded. Infants with major congenital anomalies, chromosomal abnormalities, or upper airway abnormalities are excluded. The study is conducted at participating hospitals in Chongqing, China and analyzes real-world surfactant use rather than assigning treatments.
Why it matters
Potential benefit: If successful, the study could clarify which preterm infants benefit from additional doses of surfactant and help guide treatment decisions to reduce lung injury or death.
How similar studies have gone: Surfactant replacement is well established for classic NRDS but prior reviews show inconsistent effects on bronchopulmonary dysplasia or death in some neonatal groups and surfactant has not shown clear benefit in adult/pediatric ARDS, so results are mixed rather than uniformly successful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Eligibility requirements for neonates were as follows: * The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth * The neonates will be diagnosed with NRDS or NARDS * The neonates will be at least administrated one dose of surfactant Exclusion Criteria: one of the following criteria will be needed * major congenital anomalies * chromosomal abnormalities * upper respiratory tract abnormalities
Where it's running
-
Chen
Chongqing, Chongqing Municipality, China Recruiting
Study contacts
- Study coordinator: Chen Long, MD, PhD
- Email: neuroclong@126.com
- Phone: +8613883559467
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
Cervical stiffness test to help predict preterm birth in at-risk pregnant women
A simple cervical stiffness test using the Pregnolia device is being studied to see if it can better identify women with threatened preterm labor who are likely to give birth soon.
-
Prenatal education to reduce environmental exposures during pregnancy
Aimed at pregnant people, this program tests whether a classroom-style education can help reduce exposure to harmful pollutants from seafood and nearby pollution sources.
-
Full-Course ECMO Pathway for Moderate-to-Severe ARDS
This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.
-
How doctors and nurses decide about bed rest in pregnancy
This study tests a plan to stop routinely restricting activity or bed rest during pregnancy to see if providers accept it, find it appropriate, and change how often they recommend it for women at risk of preterm birth.
-
How cervical ultrasound settings affect AI prediction of preterm birth
This study tests whether an AI model for predicting preterm birth performs differently when cervical ultrasound images are taken with different imaging settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.